Pathfinder Cell Therapy, Inc. - FORM 10-K - EX-10.24A - COMPENSATION ARRANGEMENT WITH JOHN BENSON - March 30, 2012

Attached files

file filename
EXCEL - IDEA: XBRL DOCUMENT - Pathfinder Cell Therapy, Inc.Financial_Report.xls
10-K - ANNUAL REPORT - Pathfinder Cell Therapy, Inc.f10k2011_pathfinder.htm
EX-21 - LIST OF SUBSIDIARIES - Pathfinder Cell Therapy, Inc.f10k2011ex21_pathfinder.htm
EX-31.1 - CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT - Pathfinder Cell Therapy, Inc.f10k2011ex31i_pathfinder.htm
EX-23.1 - CONSENT - Pathfinder Cell Therapy, Inc.f10k2011ex23i_pathfinder.htm
EX-32.2 - CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT - Pathfinder Cell Therapy, Inc.f10k2011ex32ii_pathfinder.htm
EX-3.2A - AMENDMENT TO BYLAWS - Pathfinder Cell Therapy, Inc.f10k2011ex3iia_pathfinder.htm
EX-31.2 - CERTIFICATION PURSUANT TO SECTION 302 OF THE SARBANES-OXLEY ACT - Pathfinder Cell Therapy, Inc.f10k2011ex31ii_pathfinder.htm
EX-10.2 - RESEARCH AND LICENSE AGREEMENT - Pathfinder Cell Therapy, Inc.f10k2011ex10ii_pathfinder.htm
EX-10.6 - STOCK OPTION PLAN - Pathfinder Cell Therapy, Inc.f10k2011ex10vi_pathfinder.htm
EX-10.22 - CONVERTIBLE PROMISSORY NOTE - Pathfinder Cell Therapy, Inc.f10k2011ex10vxii_pathfinder.htm
EX-10.24 - EMPLOYMENT AGREEMENT - Pathfinder Cell Therapy, Inc.f10k2011ex10xxiv_pathfinder.htm
EX-10.23 - CONVERTIBLE PROMISSORY NOTE - Pathfinder Cell Therapy, Inc.f10k2011ex10vxiii_pathfinder.htm
EX-32.1 - CERTIFICATION PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT - Pathfinder Cell Therapy, Inc.f10k2011ex32i_pathfinder.htm
Exhibit 10.24(a)

Compensation Arrangement with John Benson

Effective January 1, 2012, the annual salary to which Mr. John Benson is entitled under his employment agreement with Pathfinder Cell Therapy, Inc. (the “Company”) has been set at $106,923.96, reflecting a 20% reduction in the salary to which he otherwise would have been entitled.  The reduction reflects the allocation of a portion of Mr. Benson’s time to non Company-related business.

Pathfinder Cell Therapy, Inc. Reports